Gerresheimer AG
Thesis
Gerresheimer AG is positioned to benefit from the growing demand for biologics and GLP-1 drugs, which are expected to significantly increase their revenue and margins. The company has improved its financial metrics under new management, targeting a 15% blended pre-tax ROIC and a substantial increase in free cash flow as capex burdens ease. With a current trading multiple of 8-9 times EBITDA, there is potential for revaluation as they capture a larger share of the high-value solutions market.
Did it work?
Without specific price performance data or a defined time horizon for the thesis, it's difficult to assess whether the investment thesis has played out. While the company may be positioned well for future growth, the lack of concrete evidence makes it impossible to determine the success of the pitch.
Raw excerpt
No raw excerpt stored.